Stock PDI, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News PDI, Inc. Nasdaq

Equities

US69329V1008

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for PDI, Inc.
Mar. 07 Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M MT
Mar. 07 Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M
MT
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee
CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director
CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
AQ
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P
CI
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
AQ
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer
CI
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
AQ
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
AQ
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023
CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M
MT
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
AQ
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer
CI
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IDXG Stock
  4. Stock
  5. News PDI, Inc.